## Edgar Filing: Horizon Pharma plc - Form 4

Horizon Pha Form 4	ırma plc										
May 08, 201											
FORM	<b>14</b> UNITED	STATES	SECU	RITIES /	AND EX	CHANGE			PPROVAL		
Washington, D.C. 20549									3235-0287		
Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									January 31, 2005		
subject to Section 1 Form 4 c	16.		ICIAL O	Estimated average burden hours per response							
Form 5 obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17(	a) of the P	ublic U	tility Hol	lding Coi		nge Act of 1934, of 1935 or Secti 940				
(Print or Type ]	Responses)										
1. Name and A SANTINI C	2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer						
				n Pharma	• -	NP]	(Check all applicable)				
(N				3. Date of Earliest Transaction (Month/Day/Year) 05/06/2015			X_ Director 10% Owner Officer (give title Other (specify				
PLC, CON	NAUGHT HOUS LINGTON RD		03/00/2	.015			below)	below)			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					ıl	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
DUBLIN, I	.2 4							More than One R			
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, -	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	port on a separate line	e for each cla	iss of sect	urities bene	ficially ow	ned directly of	or indirectly.				
					inforr requi	nation cont red to respo ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible s	Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction of Derivative	Expiration Date	of Underlying

1

## Edgar Filing: Horizon Pharma plc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	) Ad (A Di (D (In	ecuritie cquired A) or disposed D) (nstr. 3, nd 5)	d d of	(Month/Day/Year)		Securities (Instr. 3 and 4)	
				Code N	7	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 28.53	05/06/2015		A	8	3,548		<u>(1)</u>	05/05/2025	Ordinary shares	8,548
Restricted Stock Units	<u>(2)</u>	05/06/2015		А	5	5,258		05/06/2016	(2)	Ordinary shares	5,258

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
SANTINI GINO C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON DUBLIN, L2 4	RD X							
Signatures								
/s/ Paul W. Hoelscher, Attorney-in-Fact 05/08/2	015							
**Signature of Reporting Person Date								
Explanation of Responses:								

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in 12 equal monthly installments from the date of grant.

(2) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.